LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (HK:2291) has released an update.
LEPU ScienTech Medical Technology reported a robust interim financial performance for the first half of 2024, with revenue surging by 49.7% and net profit attributable to shareholders jumping by 85.6% compared to the same period last year. The company’s gross profit also saw a significant increase of 53.4%, while research and development expenses declined by 21.3%. These figures have been reviewed by the Audit Committee and have been prepared in accordance with the China Accounting Standards for Business Enterprises (CASBE).
For further insights into HK:2291 stock, check out TipRanks’ Stock Analysis page.
